Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation

American Heart Journal

Volumn 167, Issue 3, 2014, Pages 329-334

  Huisman, Menno V ^a   Lip, Gregory Y H ^b   Diener, Hans C ^c   Dubner, Sergio J ^d   Halperin, Jonathan L ^e   Ma, Chang S ^f   Rothman, Kenneth J ^g,h   Teutsch, Christine ⁱ   Zint, Kristina ⁱ   Ackermann, Diana ⁱ   Clemens, Andreas ⁱ   Bartels, Dorothee B ^i,j  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d Clinica y Maternidad Suizo Argentina   (Argentina)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g RTI HEALTH SOLUTIONS   (United States)

^h BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DABIGATRAN;

ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; PROPENSITY SCORE; REGISTER;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FIBRINOLYTIC AGENTS; HUMANS; REGISTRIES; STROKE; TREATMENT OUTCOME;

EID: 84896709161     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.12.006     Document Type: Article

References (24)

1. Y. Miyasaka, M.E. Barnes, and B.J. Gersh et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2 2006 119 125
2. J. Heeringa, D.A.M. van der Kuip, and A. Hofman et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study Eur Heart J 27 2006 949 953
3. D.A. Fitzmaurice, F.D. Hobbs, and S. Jowett et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial BMJ 335 7616 2007 383
4. D.M. Lloyd-Jones, T.J. Wang, and E.P. Leip et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study Circulation 110 2004 1042 1046
5. A. Banerjee, F. Marín, and G.Y. Lip A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices Stroke 42 11 2011 3316 3322
6. G.Y. Lip The role of aspirin for stroke prevention in atrial fibrillation Nat Rev Cardiol 8 10 2011 602 606
7. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 12 2007 857 867
8. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. RE-LY Steering Committee and Investigators dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
9. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf et al. Randomized evaluation of long-term anticoagulation therapy investigators newly identified events in the RE-LY trial N Engl J Med 363 19 2010 1875 1877
10. M.R. Patel, K.W. Mahaffey, J. Garg RM, ROCKET AF Steering Committee, ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
11. C.B. Granger, J.H. Alexander, and J.J. McMurrax et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
12. S.J. Connolly AVERROES Steering Committee and Investigators Apixaban in patients with atrial fibrillation N Engl J Med 364 9 2011 806 817
13. C.T. Ruff, R.P. Giugliano, and E.M. Antman et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
14. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines Institute of Medicine. Clinical practice guidelines we can trust 2011 The National Academies Press Washington, DC
15. S. Schneeweiss Developments in post-marketing comparative effectiveness research Clin Pharmacol Ther 82 2 2007 143 156
16. AHRQ 2010 R.E. Gliklich, and N.A. Dreyer Registries for evaluating patient outcomes: a user's guide 2nd ed 2010 Agency for Healthcare Research and Quality
17. S. Schneeweiss, J.J. Gagne, and R.J. Glynn et al. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development Clin Pharmacol Ther 90 6 2011 777 790
18. Gerald J. Hahn, and William Q. Meeker Statistical intervals: a guide for practitioners 1991 John Wiley & Sons New York
19. R. Nieuwlaat, A. Capucci, and A.J. Camm et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation Eur Heart J 26 22 2005 2422 2434
20. J.Y. le Heuzey, G. Breithardt, and J. Camm et al. The Record-AF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation Am J Cardiol 105 2010 687 693
21. R. Nieuwlaat, M.H. Prins, and J.Y. le Heuzey et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation Eur Heart J 29 9 2008 1181 1189
22. J.P. Piccini, E.S. Fraulo, and J.E. Ansell et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF Am Heart J 162 4 2011 606 612.e1
23. A.K. Kakkar, I. Mueller, and J.P. Bassand et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD) Am Heart J 163 1 2012 13 19
24. Bassand JP, Mueller I, Mantovani LG. et al. Antithrombotic treatment patterns for stroke prevention in patients in relation to age: insights from the Global Anticoagulant Registry in the FIELD (GARFIELD) evaluation. ESC 2012, 34th Cong of the European Society of Cardiology (ESC), Munich, 25-29 Aug 2012 (Abstract).